GS Weekly Options Watch - May 11th

May 11, 2011

United States

Weekly Options Watch
Options Research

Trades: JOYG, AAPL, VRTX, UTHR
 Trade Recommendations Summary (2)
 One Page of WOW! Introducing our new one page brief summary of all of our ideas with upcoming catalysts (3)
 Options Insight: Government exposure back in the spotlight (4)
 Detailed Trade ideas: JOYG, AAPL, VRTX, UTHR (5-8)
 Additional Add Trade Recommendations: ARUN, DELL, ERIC, GPS, JWN, NIHD (2)
 The Weekly Options Watch Chartbook published today includes our Correlation, Skew, Term Structure and Sector Implied
Moves screens as well as most notable moves in the options market on the week.

Options Insight: Government exposure back in the spotlight
August puts are attractive on several stocks with high government Katherine Fogertey
(212) 902-6473 katherine.fogertey@gs.com
exposure as momentum behind deficit reduction builds. We highlight nine Goldman Sachs & Co.
stocks with an average of 69% of sales coming from government sources,
but each has implied volatility below median levels over the past year. LLL, John Marshall
LMT, NOC, DELL, RTN, UNH, XRX, HUM, and GD. (212) 902-6848 john.marshall@gs.com
Goldman Sachs & Co.

Trades: JOYG, AAPL, VRTX, UTHR
Trade 1: Buy calls on JOYG; Expecting a significantly better quarter.
We’d buy attractive calls to express a bullish view ahead of the quarter.
Our analyst is significantly above the Street; sees strong M&A potential.
Trade 2: Buy Apple June Vol for June 6th Dev. Conf., a catalyst more
stock moving than earnings. Apple shares tend to be even more volatile
around the Developer’s Conference than earnings. Our analyst sees this as
an important positive catalyst for shares and expects the company to
discuss their cloud offering, a critical driver of the longer term outlook for
the company. Implied vol of 21% is near all time lows and not pricing in
this average +/-5.4% moving event, in our view.
Trade 3: Buy VRTX July Calls: 3 Important Catalyst, M&A potential.
Expecting upcoming Merck Boceprevir data, better than expected cystic
fibrosis treatment data, and TVR data on May 23 to drive substantial upside
in shares. Following data, our analyst sees high potential for M&A.
Trade 4: Buy UTHR Aug $75 Calls for FREEDOM data in June; Close
Jan-12 $90 Call Sale. Our analyst has high conviction in FREEDOM data in
June. We would use gains on the call sale to add to long August $75 calls
ahead of this key data. Our analyst sees a strong potential for M&A.

Trade Update: Close 1 trade at gain (UTHR) and 1 trade at loss (PCLN); 1
trade was previously closed at gain (CMCSA).

The Goldman Sachs Group, Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be
aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single
factor in making their investment decision. For Reg AC certification, see the end of the text. Other important disclosures follow the Reg AC
certification, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts
with FINRA in the U.S. This report is intended for distribution to GS institutional clients only.

The Goldman Sachs Group, Inc. Goldman Sachs Global Economics, Commodities and Strategy Research

Trade recommendations summary
We recommend adding to 10 positions, continuing to hold 6 positions, and closing 2
positions this week. 1 trade was closed on 4-May. The table below focuses on the catalyst-
based recommendations discussed in the WOW; for our macro and thematic
recommendations please refer to our other Cross-Product reports on our portal.

Exhibit 1: Trade recommendations summary
Recommendations and indicative prices as of 10-May
Initial price Current price

Stock Trade Description Initiation date Stock Trade Stock Trade
Add to these trade recommendations
AAPL BUY JUN-11 $350 STRADDLE 11-May-11 349.45 19.40 349.45 19.40
ARUN BUY JUL-11 $33 CALL / SELL JAN-12 $40 CALL 24-Mar-11 31.42 0.30 32.71 -0.30
DELL BUY JUN-11 $15/$16 1X2 PUT SPREAD 4-May-11 15.80 0.06 16.41 0.02
ERIC BUY JUL-11 $15 CALL 4-May-11 14.98 0.75 15.38 0.95
GPS BUY JUN-11 $23 PUT 4-May-11 22.93 0.95 22.98 0.87
JOYG BUY JUN-11 $95 CALL 11-May-11 92.80 3.55 92.80 3.55
JWN BUY JUN-11 $49 CALL 4-May-11 48.10 1.45 48.26 1.36
NIHD BUY JUN-11 $41 CALL 2-Mar-11 39.65 2.67 44.06 3.80
UTHR BUY AUG-11 $75 CALL 9-Mar-11 68.69 8.39 66.69 4.50
VRTX BUY JUL-11 $55 CALL 9-May-11 54.54 3.90 57.05 5.70
Continue to hold these trade recommendations
AMT BUY JAN-12 $50 CALL 16-Mar-11 50.02 5.30 53.69 7.00
BAC SELL JAN-13 $12.5/$25 STRANGLE 11-Feb-11 14.49 2.35 12.28 2.25
DIS SELL OCT-11 $45 COVERED CALL 27-Apr-11 42.33 1.54 43.91 2.14
JPM SELL JAN-13 $40/$60 STRANGLE 11-Feb-11 45.53 6.38 45.16 5.89
NOK BUY MAY-11 $8/$9 STRANGLE 6-Apr-11 8.77 0.55 8.74 0.14
VMC BUY MAY-11 $36/$41 PUT SPREAD 9-Mar-11 44.00 1.25 41.76 0.60
Close these trades
PCLN BUY JUN-11 $525/$590 1X2 CALL SPREAD 20-Apr-11 525.53 16.05 528.50 14.60
UTHR SELL JAN-12 $90 CALL 9-Mar-11 68.69 5.80 66.69 4.60
Previously Closed Trades
CMCSA BUY JUN-11 $25 CALL 20-Apr-11 24.29 0.62 26.22 1.61

Full trade idea references with risks: Legend:
GPS, ERIC, PCLN, JWN, DIS, NIHD, DELL trade ideas (3-May) Add to these trade recommendations: These are open
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10965563&fn=/document.pdf trade ideas where we think there remains a good
CMCSA trade closing (4-May) opportunity for investors to add new money. We believe the
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10970005&fn=/document.pdf trade is still attractive, the majority of the catalysts have not
NIHD, AMT trade ideas (26-April) yet happened and there is still a significant portion of the
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10919110&fn=/document.pdf time to expiration.
NOK trade idea (6-April) Continue to hold these trade recommendations: These
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10808751&fn=/document.pdf are open trade ideas where we think the risk/reward on the
UTHR trade idea (9-Mar) trade is still favorable; we recommend that investors who
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10647114&fn=/document.pdf hold the position continue to do so. We would not
BAC, JPM trade ideas (11-Feb) recommend adding new money for one of the following
https://360.gs.com/gs/portal/?st=1&action=action.binary&d=10494465&fn=/document.pdf reasons: (1) many of the key catalysts have passed, (2) the
trade has moved significantly toward the place we
expected it to move to, or (3) there is not enough time
Close these trades: With this report, we close our
recommendations on these trade ideas for one of the
following reasons: (1) the major catalysts have passed, (2)
the fundamental thesis has changed, or (3) the trade has
already moved to where we thought it should.

Source: Goldman Sachs Global Research estimates, Bloomberg.

Exhibit 1: One Page of WOW!
Brief overview of our trade recommendations with upcoming catalysts .
Current Price of Imp. Move on Volatility from
Trade Earnings from 1- Option Trade Brief Summary of Trade Thesis
Recommendation mth Options Idea
Trade Catalyst Stock Option Imp. 8Q Med. Imp. Real. For more details on our trade ideas and risks, please reference Exhibit 1.
Thursday, May 12, 2011
NIHD BUY JUN-11 $41 CALL Analyst Meeting $44.06 $3.80 9% 5% 31 23 Buy calls ahead of Analyst Day -- our analyst expects management to discuss a software patch that will enable
NIHD to offer 3G services. Implied vol of 32% is not pricing in a strong move in our view.
ERIC BUY JUL-11 $15 CALL Analyst Meeting $15.38 $0.95 n/a n/a 26 28 With implied volatility lower post earnings ahead of a potential stock moving catalyst (Analyst Meetings on May
12), we view calls as attractive stock replacement to equity positions, especially considering our analyst's longer
term concerns, including peaking gross margins and business mix. Implied vol is near 1 yr lows.
JWN BUY JUN-11 $49 CALL Earnings $48.26 $1.36 5% 3% 30 17 Our analyst sees upside risk to estimates for the quarter and FY2011. JWN is benefiting from a healthy consumer
who is less affected by rising gas prices. Department stores are better positioned to get more favorable pricing
from vendors, helping to offset cost inflation.
Tuesday, May 17, 2011
DELL BUY JUN-11 $16/$15 1X2 Earnings $16.41 $0.02 8% 4% 36 28 Options are implying a +/- 8% move on earnings vs median 8 qtr move of +/-4%. With most of the supply chain
PUT SPREAD already reporting, our analyst does not see a significant surprise for DELL. Importantly, while tablets are a risk to
shares, DELL's heavy enterprise exposure could mitigate the near term impact. Additionally, DELL is developing
its own tablet offering geared to the enterprise. Breakeven: $14.06 to $16.06 on expiration.
Thursday, May 19, 2011
ARUN BUY JUL-11 $33 CALL Earnings $32.71 $2.90 10% 11% n/a n/a Key beneficiary of enterprise tablet adoption. Analyst sees 18% upside to shares.
SELL JAN-12 $40 CALL
GPS BUY JUN-11 $23 PUT Earnings $22.98 $0.87 4% 2% 30 21 Our analyst sees downside risks to earnings given (1) exposure to lower end consumer makes passing on cost
inflation more difficult; (2) tough comps from Old Navy; (3) near peak gross margins; (4) balance sheet
restructuring.
VRTX BUY JUL-11 $55 CALL Boceprevir Data $57.05 $5.70 n/a n/a 41 50 Our analyst is positive on VRTX ahead of three catalysts, including the all important May 23, 2011 TVR study
(this week) / CF data. He sees VRTX as a compelling M&A candidate following approval for this important drug, where he is more
Data / May 23 positive on both the label and the pricing potential for the drug. Implied vol of 41% is 89 points below recent
TVR Data realized in the name.

Thursday, June 02, 2011
JOYG BUY JUN-11 $95 CALL Earnings $92.80 $3.55 5% 4% 39 38 Our analyst is expecting a significantly better quarter for Buy rated JOYG, supported by improving seasonality,
stronger than expected supply / demand dynamics evidenced by BUCY results this quarter, a bullish view on
mining capex budgets, and a longer term bullish stance on M&A potential. Options are implying a +/-5% move on
earnings, inline with average. Our analyst has 30% upside to 12-mth price target of $120.
Monday, June 06, 2011
AAPL BUY JUN-11 $350 Earnings $349.45 $19.40 5% 3% 22 17 Implied volatility of June options appears too low to us, trading close to all time lows, considering that Apple
STRADDLE shares have averaged a 5 day move of -5.4% on their Worldwide Developers Conference, more than the average
move on earnings of +/-3%. Our analyst sees 35% upside to CL-Buy rated shares and is bullish on near term
catalysts.

Source: Goldman Sachs Research estimates; pricing as of May 9, 2011. * Option vol for applicable term. For 22mth options, we compare to 24 month realized vol. For all other terms, where applicable, we compare to
recent realized for the same term as implied.

Options Insight: Hedge stocks with government spending exposure
August puts are attractive on several stocks with high government exposure as
momentum behind deficit reduction builds. We highlight nine stocks with an average of
69% of sales coming from government sources, but each has implied volatility below
median levels over the past year. LLL, LMT, NOC, DELL, RTN, UNH, XRX, HUM, and GD.

Government spending reductions have already impacted company results. Over the
past six months, CSC, CSCO, UIS, LLL, IBM and several other companies have noted the
negative impact of government spending reductions on their results or orders. We see the
potential for more anecdotal evidence to emerge.

Deficit reduction momentum likely to continue: Our Washington, D.C. analyst Alec
Philips and our Economics Research team note that the growing momentum behind deficit
reduction implies the possibility of greater spending cuts and/or tax expirations than they
are currently assuming. In light of the upcoming catalysts, they expect investors to
continue to focus on the impact of deficit reduction:

 This week: President is expected to meet with Senate Democrats and Republicans. The
House is expected to set top-line appropriations for FY2012.

 Week of May 16: The debt limit is reached and the Treasury will likely begin accounting
maneuvers to avoid increased borrowing. Senator Conrad may release a budget
resolution draft.

 August 2: Our economists expect the treasury to exhaust accounting strategies.

 August: The Congressional budget office is scheduled to release an updated budget
outlook.

Exhibit 2: Buy puts to hedge stocks with high government exposure, low implied vol and low put skew
Government exposure is greater than 25%, Analyst Neutral or Sell Rated, 3-mth implied volatility and normalized skew is below
50th percentile over past year

Upside YTD 52 Next 3-mth Option Stats 3-month
% Sales Analyst Stock to 12m Price Week Earnings Imp. Imp - Norm. 5% OTM
Sector to Gov't Rating Price Target % Low Date Vol %-ile Real %-ile Skew %-ile put cost
DELL Hardware 27% S $16.19 (32%) 19% $11.34 17-May 32 40% (2) 22% 0.10 4% 4%
LLL Industrials 91% S $83.22 (16%) 18% $66.11 26-Jul 21 6% 4 74% 0.16 17% 3%
NOC Industrials 90% S $64.81 (14%) 10% $48.53 29-Jul 22 14% 5 80% 0.11 0% 3%
LMT Industrials 97% S $79.93 (12%) 14% $67.68 26-Jul 19 11% 3 47% 0.15 27% 2%
RTN Industrials 88% N $49.51 (11%) 7% $42.65 29-Jul 21 13% 4 83% 0.13 9% 3%
GD Industrials 80% N $74.57 3% 5% $55.46 28-Jul 22 15% 1 43% 0.19 23% 3%
XRX Hardware 30% N $10.18 8% (12%) $7.67 28-Jul 30 28% 6 83% 0.13 21% 4%
HUM Healthcare 81% N $77.09 9% 41% $43.17 1-Aug 28 16% 4 20% 0.12 11% 4%
UNH Healthcare 36% N $50.47 13% 40% $27.13 19-Jul 26 20% 3 19% 0.16 41% 3%
average 69% (6%) 25 18% 52% 17% 3%

Source: Goldman Sachs Research estimates.

Options prices on stocks with high government sales exposure are in-line with the
average stock in the S&P 500, despite higher fundamental risk. 3 month implied
volatility for the nine stocks we highlight is 25%, in-line with the average stock in the S&P
500. Despite the increased focus on potential decreases in government spending, implied
volatility has traded in-line with the average stock over the past several months. We favor
buying puts on these stocks now, while implied volatility is in its 18th percentile on average.
We believe that buying puts on these stocks is also attractive for investors looking to hedge
government exposure risk in their portfolio. We see the potential for correlation between

May 11, 2011 United States

these stocks to rise off low levels as government spending risk comes into focus. Basket
option buyers benefit from a rise in correlation.

Exhibit 3: Options prices on gov’t exposed stocks are no more expensive than average
3 month implied volatility for our basket of 10 stocks; S&P 500 average stock implied vol

40
Average stock vol
38
Government exposure stock vol
3 month implied volatility
36

34

32

30

28

26

24

22
8-May 8-Aug 8-Nov 8-Feb 8-May

Source: Goldman Sachs Research estimates.

Puts on defense stocks are particularly attractive (LLL, LMT, NOC)
ahead of catalysts
Goldman Sachs aerospace and defense analyst Noah Poponak sees headwinds to defense
stocks and recommends that investors sell shares. He believes the assignment of Leon
Panetta to be the next Secretary of Defense, replacing Robert Gates, and Army General
David Petraeus becoming Director of the CIA (pending Senate approval) could have
negative implications for defense stocks. He sees these two appointments as likely to
curtail spending and focus heavily on expense control. He sees this as one more example
of pressure on Department of Defense spending, which he sees lasting for an extended
period of time given long spending cycles. Further, he sees valuation as rich taking into
account downward revisions to the FY2012 plan. Three month puts capture continued
budget catalysts and earnings.

Goldman Sachs Global Economics, Commodities and Strategy Research 5


Trade 1: Buy calls on JOYG; Expecting a significantly better quarter
Buy June $95 calls for $3.55 (3.8% of stock, $92.80) ahead of earnings 2-June and
M&A potential. Goldman Sachs Machinery analyst Jerry Revich sees 29% upside to his
12-mth price target of $120 on Buy rated shares, and sees 13% upside to consensus
2QFY2011 estimate of $1.35 driven by sharply higher aftermarket demand and operating
leverage. For next quarter, he expects JOYG to report $1.63, nearly 14% above the Street’s
$1.43 estimate. Key reasons why he is bullish:

• Strong read-across from competitor BUCY’s results: JOYG’s largest competitor,
BUCY, reported 20% sales growth in underground mining and around 10% organic
growth in Surface driven by rising parts consumption on recently installed
machines. Our analyst notes that new equipment orders were also strong, with a
very robust 1.9X book to bill. He sees this as a positive data point for industry
demand and supporting his 17% above Street estimates for JOYG (2012E $7.55
EPS vs Street $6.46) and his thesis that seasonality is improving for the mining
equipment stocks.

• Industry Supply/Demand Dynamics Work in JOYG’s Favor: Tight mine supply
constraints will drive mining costs and aftermarket sales meaningfully higher over
the course of this cycle.

• Mining capex budgets still too low: Consensus views of a meaningful slowdown
in mining capex later in this cycle will continue to be revised higher.

Options are not pricing in strong fundamental trends for JOYG, or M&A potential.
With three month implied vol at 39%, only 5% from one year lows, we recommend that
investors buy options ahead of earnings. We recommend June options over longer dated
options given a surprisingly flat to upward sloping term structure, in sharp contrast to our
analyst’s strong views around the potential for M&A. In fact, he incorporates a 30%
probability of M&A in his 12-month price target (M&A Value $136) and sees CAT’s recent
bid for BUCY as a strong leading indicator that JOYG too will be acquired. One month
normalized skew is moderate, suggesting a more balanced relationship between put and
call demand. Investors who buy call options risk loss of the entire premium paid if the
underlying security finishes below the strike price at expiration.

Trade 2: Buy Apple June Vol for June 6 Dev. Conf., a catalyst more
stock moving than earnings
Buy June $350 straddles for $19.40 (5.5%, stock at $349.45) ahead of June 6
Developer’s Conference; vol near all-time lows yet shares move more on this event
than on earnings. Our Hardware Analyst Bill Shope rates Apple shares CL-Buy and sees
35% upside to his 12-month price target of $470. Apple shares are now trading at just 11X
his 2012 EPS, a 50% discount to the average multiple of 22X, despite 22% growth in 2012,
largely due to concerns around supply chain disruptions. We view implied volatility in June
options as attractive, at just 21% which is near all time lows and a reasonable 4 points over
recent realized, ahead of the June 6 Developer’s Conference.

June 6: Developers Conference is likely to be an important catalyst for shares, even
more than earnings. Our analyst expects Apple to focus on Apple’s upcoming cloud
services, which should further propel the company’s iOS platform ahead of the leading
tablet and smartphone competition. He views this as an important positive catalyst for the
stock and to further solidify Apple’s lasting competitive advantage versus smartphone
peers. While our analyst is positive on this catalyst, we note that in each of the seven years,



Apple shares have traded lower the five days around the WorldWide Developer’s
Conference (average move -5.4%). To put this in comparison, the average move of Apple
shares on earnings over the past eight quarters has only been +/-3%.

Our analyst believes that supply chain hiccups generally offer the best opportunities
for Apple’s stock, and he sees this time with iPhone and iPad as no different. The
iPhone refresh now is being pushed out to September (which is actually a positive for June
sales versus expectations), and the iPad2 sales last quarter were below expectations given
tight supplies. Importantly for these two products, he doesn’t see the delay in the iPhone
refresh as impacting sales given it will be ready for the all important December selling
season. Our analyst views Apple as the best positioned company to handle supply chain
disruptions given their large size and importance in the marketplace.

We’d buy inexpensive Apple options ahead of the Developers Conference. One month
implied volatility of 22% is trading near historical low of 20% (going back to 1996) and
versus recent realized of 18%. While options are trading 4 points over realized, typically
rich for Apple, we see average move of -5% around the Developer’s Conference, combined
with our analyst’s strong upside view on shares, as a key catalyst to buy vol, given the
average daily move of shares +/-1.1%. If held to expiration, June $350 straddle buyers profit
if shares close up 5.7% to $369.40 or down 5.4% to $330.60 on June expiration. Investors
who hold straddles to expiry risk losing their entire premium paid.

Trade 3: Buy VRTX July Calls: 3 Important Catalyst, M&A potential
Buy July $55 calls for $5.70 (10% of stock, $57.05) ahead of three key drug catalysts
and M&A potential. Goldman Sachs SMid Cap Biotechnology Analyst Terence Flynn
expects three upcoming catalysts to be positive for Buy-rated VRTX. Following the
upcoming May 23 approval date for VRTX’s key drug, TVR, he believes VRTX may become
a more attractive M&A value of $87.

 This week: Approval of Merck’s Boceprevir (and pricing decision) should be
stock moving for VRTX. MRK’s competitor drug Boceprevir could be approved
first and set the pricing bar. While he is positive on the potential for both drugs, he
recommends adding to VRTX positions in the event of any weakness.

 This month: “Significant” upside potential to shares from CF combo data;
market opportunity could be double vs low expectations. While TVR for hepC
is the major driver of VRTX, our analyst is bullish on the potential for the
company’s emerging cystic fibrosis (CF) drug pipeline. He expects VRTX to report
interim data this quarter (he expects May) from a Phase 2 CF trial of VX-770 in
combo with VX-770 (less than $500 mn). While this is not central to his bullish
view on VRTX shares, he sees the CF pipeline (treatment opportunity) as
underappreciated by investors, especially given low expectations for success.

 May 23: TVR approval date – Broader label, higher pricing, expecting positive
catalyst for shares. Our analyst expects TVR to have a broader label than MRK’s
Boceprevir and he is above consensus for TVR pricing at $45k/yr.

Buy options as these three significant catalysts to drive should drive realized
volatility, and shares, higher. We recommend that investors buy the July $55 calls for
$5.70 (10% of stock, $57.05). Three month implied vol of 41% is 9 points below realized,
and in line with its 1-yr median. We view options as attractive in light of significant stock
moving catalysts. We would buy July options instead of June given a downward sloping
term structure, opportunity to capture more catalysts, potential risk of key catalysts



slipping, and M&A potential. Investors who buy call options risk loss of the entire premium
paid if the underlying security finishes below the strike price at expiration.

Trade 4: Buy UTHR Aug $75 Calls for FREEDOM data in June; Close
Jan-12 $90 Call Sale
Buy UTHR Aug $75 Calls for $4.50 (6.7%, stock $66.69) ahead of June FREEDOM data
and close the Jan-12 $90 call sale at a gain. On March 9, we recommended that investors
buy the August $75 call for $8.39 (stock $68.69), and sell the Jan-12 $90 call for $5.80 to
help fund the purchase ahead of several key catalysts, including earnings and June data on
FREEDOM, the biotech’s main drug to treat Pulmonary Arterial Hypertension (PAH). As we
get closer to the critical June date, we recommend that investors close the Jan-12 call sale
at a gain (ask $4.60) and add to August $75 calls, to increase upside potential into the event.
Our SMid Cap biotechnology analyst Terence Flynn rates UTHR shares Buy and sees 23%
upside to his $82 12-month price target.

Mid-June Phase 3 trial data is a critical PAH catalyst. Key upcoming catalysts center
around Phase 3 trial trail results for FREEDOM-M in June and FREEDOM-C2 in September.
These trials are studying FREEDOM as the new oral formulation of the company’s franchise
drug Remodulin for PAH. Our analyst is more optimistic than the Street that this drug will
succeed in Phase 3 and expects positive data from the first trial in mid-2011 in June. He
expects that the approval of oral Remodulin would move this drug class upstream to
first/second line patients (a $1bn+ market opportunity) and drive long-term growth; he
continues to model 2015 sales of oral Remodulin of $400mn vs. consensus of $0-$200mn.

Our analyst is more optimistic than the market that oral Remodulin will succeed in
Phase 3 and assigns a 75% probability of success to the FREEDOM trials. (1) While the
initial Phase 3 trial of oral Remodulin (FREEDOM-C, released in 2008) did not meet the
primary endpoint, he believes the trial demonstrated that the drug has activity, based on a
subset analysis of the data. (2) He notes that the new titration schedule of oral Remodulin
appears to be having a positive impact on tolerability in the ongoing FREEDOM-M and
FREEDOM-C2 Phase 3 trials, based on blinded discontinuation rates from the trials. (3)
Dose titration has been used successfully for prostanoid drugs (Remodulin, Flolan and
Beraprost). (4) The monotherapy design of FREEDOM-M (the first Phase 3 trial that will
read out) represents a low hurdle to demonstrate a benefit.

Options are not pricing in nearly enough volatility, in our view, for June – September
timeframe, and are not reflecting M&A potential. We’d expect implied volatility to move
higher for Aug options given the importance of this catalyst. In fact, we’ve recently seen
biotech options trade at much more significant premiums ahead of this type of catalyst. 3m
implied vol of 54% is elevated versus 3-mth realized of 20% but likely to stay bid, in our
view, until this important catalyst passes. Investors who buy call options risk loss of the
entire premium paid if the underlying security finishes below the strike price at expiration.

Readers please note, we are now including the screens typically found in the back of our Weekly Options Watch in
The Weekly Options Watch Chartbook, also published today.

Rating and pricing information
Apple Inc. (B/N, $349.45), Joy Global Inc. (B/N, $92.80), United Therapeutics Corporation
(B/N, $66.69) and Vertex Pharmaceuticals, Inc. (B/N, $57.05).



Reg AC
We, Katherine Fogertey and John Marshall, hereby certify that all of the views expressed in this report accurately reflect our personal views about the
subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly,
related to the specific recommendations or views expressed in this report.

Disclosures

Option Specific Disclosures
Price target methodology: Please refer to the analyst’s previously published research for methodology and risks associated with equity price
targets.
Pricing Disclosure: Option prices and volatility levels in this note are indicative only, and are based on our estimates of recent mid-market levels.
All prices and levels exclude transaction costs unless otherwise stated.
Buying Options - Investors who buy call (put) options risk loss of the entire premium paid if the underlying security finishes below (above) the
strike price at expiration. Investors who buy call or put spreads also risk a maximum loss of the premium paid. The maximum gain on a long call or
put spread is the difference between the strike prices, less the premium paid.
Selling Options - Investors who sell calls on securities they do not own risk unlimited loss of the security price less the strike price. Investors who
sell covered calls (sell calls while owning the underlying security) risk having to deliver the underlying security or pay the difference between the
security price and the strike price, depending on whether the option is settled by physical delivery or cash-settled. Investors who sell puts risk loss of
the strike price less the premium received for selling the put. Investors who sell put or call spreads risk a maximum loss of the difference between
the strikes less the premium received, while their maximum gain is the premium received.
For options settled by physical delivery, the above risks assume the options buyer or seller, buys or sells the resulting securities at the
settlement price on expiry.

Company-specific regulatory disclosures
The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies
covered by the Global Investment Research Division of Goldman Sachs and referred to in this research.
Goldman Sachs has received compensation for investment banking services in the past 12 months: Apple Inc. ($349.45)
Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Apple Inc. ($349.45), Joy
Global Inc. ($92.80) and Vertex Pharmaceuticals, Inc. ($57.05)
Goldman Sachs has received compensation for non-investment banking services during the past 12 months: Apple Inc. ($349.45)
Goldman Sachs had an investment banking services client relationship during the past 12 months with: Apple Inc. ($349.45), Joy Global Inc. ($92.80)
and Vertex Pharmaceuticals, Inc. ($57.05)
Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Apple Inc. ($349.45)
Goldman Sachs had a non-securities services client relationship during the past 12 months with: Apple Inc. ($349.45)
Goldman Sachs makes a market in the securities or derivatives thereof: Apple Inc. ($349.45), Joy Global Inc. ($92.80), United Therapeutics
Corporation ($66.69) and Vertex Pharmaceuticals, Inc. ($57.05)
Goldman Sachs is a specialist in the relevant securities and will at any given time have an inventory position, "long" or "short," and may be on the
opposite side of orders executed on the relevant exchange: Apple Inc. ($349.45), United Therapeutics Corporation ($66.69) and Vertex
Pharmaceuticals, Inc. ($57.05)

Disclosures required by United States laws and regulations
See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager
or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-
managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs usually makes a
market in fixed income securities of issuers discussed in this report and usually deals as a principal in these securities.
The following are additional required disclosures: Ownership and material conflicts of interest: Goldman Sachs policy prohibits its analysts,
professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.
Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. Analyst
as officer or director: Goldman Sachs policy prohibits its analysts, persons reporting to analysts or members of their households from serving as an
officer, director, advisory board member or employee of any company in the analyst's area of coverage. Non-U.S. Analysts: Non-U.S. analysts may
not be associated persons of Goldman Sachs & Co. and therefore may not be subject to NASD Rule 2711/NYSE Rules 472 restrictions on
communications with subject company, public appearances and trading securities held by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States
The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws
and regulations. Australia: This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian
Corporations Act. Canada: Goldman Sachs & Co. has approved of, and agreed to take responsibility for, this research in Canada if and to the extent it
relates to equity securities of Canadian issuers. Analysts may conduct site visits but are prohibited from accepting payment or reimbursement by the
company of travel expenses for such visits. Hong Kong: Further information on the securities of covered companies referred to in this research may
be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this



research may be obtained from Goldman Sachs (India) Securities Private Limited; Japan: See below. Korea: Further information on the subject
company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. Russia: Research reports
distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product
promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Singapore: Further
information on the covered companies referred to in this research may be obtained from Goldman Sachs (Singapore) Pte. (Company Number:
198602165W). Taiwan: This material is for reference only and must not be reprinted without permission. Investors should carefully consider their
own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as
retail clients in the United Kingdom, as such term is defined in the rules of the Financial Services Authority, should read this research in conjunction
with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by
Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from
Goldman Sachs International on request. Brazil: Disclosure information in relation to CVM Instruction 483 is available at
http://www.gs.com/worldwide/brazil/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this
research report, as defined in Article 16 of CVM Instruction 483, is the first author named at the beginning of this report, unless indicated otherwise at
the end of the text.
European Union: Disclosure information in relation to Article 4 (1) (d) and Article 6 (2) of the European Commission Directive 2003/126/EC is available
at http://www.gs.com/client_services/global_investment_research/europeanpolicy.html which states the European Policy for Managing Conflicts of
Interest in Connection with Investment Research.
Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer under the Financial Instrument and Exchange Law, registered with the Kanto
Financial Bureau (Registration No. 69), and is a member of Japan Securities Dealers Association (JSDA) and Financial Futures Association of Japan
(FFAJ). Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific
disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese
Securities Finance Company.

Ratings, coverage groups and views and related definitions
Buy (B), Neutral (N), Sell (S) -Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy
or Sell on an Investment List is determined by a stock's return potential relative to its coverage group as described below. Any stock not assigned as
a Buy or a Sell on an Investment List is deemed Neutral. Each regional Investment Review Committee manages various regional Investment Lists to a
global guideline of 25%-35% of stocks as Buy and 10%-15% of stocks as Sell; however, the distribution of Buys and Sells in any particular coverage
group may vary as determined by the regional Investment Review Committee. Regional Conviction Buy and Sell lists represent investment
recommendations focused on either the size of the potential return or the likelihood of the realization of the return.
Return potential represents the price differential between the current share price and the price target expected during the time horizon associated
with the price target. Price targets are required for all covered stocks. The return potential, price target and associated time horizon are stated in each
report adding or reiterating an Investment List membership.
Coverage groups and views: A list of all stocks in each coverage group is available by primary analyst, stock and coverage group at
http://www.gs.com/research/hedge.html. The analyst assigns one of the following coverage views which represents the analyst's investment outlook
on the coverage group relative to the group's historical fundamentals and/or valuation. Attractive (A). The investment outlook over the following 12
months is favorable relative to the coverage group's historical fundamentals and/or valuation. Neutral (N). The investment outlook over the following
12 months is neutral relative to the coverage group's historical fundamentals and/or valuation. Cautious (C). The investment outlook over the
following 12 months is unfavorable relative to the coverage group's historical fundamentals and/or valuation.
Not Rated (NR). The investment rating and target price have been removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an
advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances. Rating Suspended (RS). Goldman
Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for
determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and
price target, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended
coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company. Not Available or Not Applicable (NA). The information
is not available for display or is not applicable. Not Meaningful (NM). The information is not meaningful and is therefore excluded.

Global product; distributing entities
The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs, and pursuant
to certain contractual arrangements, on a global basis. Analysts based in Goldman Sachs offices around the world produce equity research on
industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in
Australia by Goldman Sachs & Partners Australia Pty Ltd (ABN 21 006 797 897) on behalf of Goldman Sachs; in Canada by Goldman Sachs & Co.
regarding Canadian equities and by Goldman Sachs & Co. (all other research); in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman
Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul
Branch; in New Zealand by Goldman Sachs & Partners New Zealand Limited on behalf of Goldman Sachs; in Russia by OOO Goldman Sachs; in
Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co.
Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union.
European Union: Goldman Sachs International, authorized and regulated by the Financial Services Authority, has approved this research in
connection with its distribution in the European Union and United Kingdom; Goldman Sachs & Co. oHG, regulated by the Bundesanstalt für
Finanzdienstleistungsaufsicht, may also distribute research in Germany.

General disclosures
This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we
consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as
appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large
majority of reports are published at irregular intervals as appropriate in the analyst's judgment.
Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have
investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research
Division. Goldman Sachs & Co., the United States broker dealer, is a member of SIPC (http://www.sipc.org).



Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our
proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, our
proprietary trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views
expressed in this research.
We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in,
act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.
This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be
illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of
individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if
appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them
may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur.
Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.
Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors.
Investors should review current options disclosure documents which are available from Goldman Sachs sales representatives or at
http://www.theocc.com/about/publications/character-risks.jsp. Transactions cost may be significant in option strategies calling for multiple purchase
and sales of options such as spreads. Supporting documentation will be supplied upon request.
All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all
research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our
research by third party aggregators. For all research available on a particular stock, please contact your sales representative or go to
http://360.gs.com.
Disclosure information is also available at http://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY
10282.
Copyright 2011 Goldman Sachs.
No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior
written consent of The Goldman Sachs Group, Inc.


GS Weekly Options Watch - May 11th

Recomendados

Mais conteúdo relacionado

Mais de James Hilbert

Mais de James Hilbert (20)

Último

Último (20)

GS Weekly Options Watch - May 11th